<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>71</patient-age><report-id>US-PFIZER INC-2013031486</report-id><gender>female</gender><reactions><reaction>dry skin</reaction><reaction>change in skin color</reaction><reaction>pregabalin was not as effective as it was in the past</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>Lyrica</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ASPIRIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>VICODIN</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Pain foot</indication><indication>Heart disease, unspecified</indication></indications><patient-age>71</patient-age><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>psur</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4254123_P31</messagenumb>
		<messagesenderidentifier>PFIZERINC</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151551</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>US-PFIZER INC-2013031486</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="2">No</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-23</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-23</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>2</fulfillexpeditecriteria>
		<companynumb>US-PFIZER INC-2013031486</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>PFIZERINC</senderorganization>
			<senderfamilyname>Head Drug Safety Surveillance</senderfamilyname>
			<senderstreetaddress>150 East 42nd Street</senderstreetaddress>
			<sendercity>New York</sendercity>
			<senderstate>New York</senderstate>
			<senderpostcode>10017</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2127335544</sendertel>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20785</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3019183134</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientonsetage>71</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientweight>104.31</patientweight>
			<patientheight>168</patientheight>
			<patientsex code="2">Female</patientsex>
			<resultstestsprocedures>Unspecified blood work (Nov2012): normal</resultstestsprocedures>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Heart disease, unspecified</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalcomment>taking unspecified medication and aspirin</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Walking difficulty</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalcomment>due to which she was using walking cane</patientmedicalcomment>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>dry skin</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Dry skin</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dry skin</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>change in skin color</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Skin discolouration</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Skin discolouration</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>pregabalin was not as effective as it was in the past</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Drug ineffective</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Drug ineffective</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>Lyrica</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>21-446</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Pfizer, Inc.</drugauthorizationholder>
				<drugstructuredosagenumb>200</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>3</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>200 mg, 3x/day</drugdosagetext>
				<drugdosageform normalized="capsule, hard">Capsule, hard</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Pain foot</drugindication>
				<actiondrug code="4">Dose not changed</actiondrug>
				<drugadditional code="ExpDT=27-NOV-2013"/>
				<activesubstance>
					<activesubstancename>PREGABALIN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dry skin</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dry skin</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Skin discolouration</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Skin discolouration</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<drugdosagetext>UNK</drugdosagetext>
				<activesubstance>
					<activesubstancename>INSULIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<drugdosagetext>UNK</drugdosagetext>
				<activesubstance>
					<activesubstancename>HYDROCHLOROTHIAZIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>ASPIRIN</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Heart disease, unspecified</drugindication>
				<activesubstance>
					<activesubstancename>ACETYLSALICYLIC ACID</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>VICODIN</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<activesubstance>
					<activesubstancename>HYDROCODONE BITARTRATE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This is a spontaneous report from a non clinical study program <Semaphore x="804590" class="Medicine" value="Lyrica" score="0.74" ID="275868">Lyrica </Semaphore>Answers from a contactable consumer reporting for self. This 71-year old <Semaphore x="2699001" class="Race" value="White" score="1.00" ID="C41261">White female </Semaphore>patient started taking <Semaphore x="1082033" class="Medicine" value="pregabalin" score="0.93" ID="239993">pregabalin </Semaphore>(<Semaphore x="804590" class="Medicine" value="Lyrica" score="0.74" ID="275868">LYRICA</Semaphore>, Expiration Date: 27Nov2013) 200mg <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore>capsule three times a day for <Semaphore x="2905647" class="MedDRA LLT" value="Diabetic foot" score="1.00" ID="10060734">diabetic <Semaphore x="1944124" class="Disease or Finding" value="Foot Pain" score="1.00" ID="C34618">pain in <Semaphore x="1944242" class="AnatomicStructure" value="Foot" score="1.00" ID="C32622">feet </Semaphore></Semaphore></Semaphore>on an unknown date. Relevant medical history included unspecified <Semaphore x="2010398" class="AnatomicStructure" value="Heart" score="1.00" ID="C12727">heart </Semaphore>condition and problem in <Semaphore x="1936750" class="Procedure" value="Findings-Based Question" score="0.58" ID="C91103">walking </Semaphore>due to which she was using walking cane and the medical history conditions were ongoing during the events. Concomitant medications included <Semaphore x="733661" class="Medicine" value="Insulin" score="0.49" ID="275827">insulin</Semaphore>, <Semaphore x="675434" class="Medicine" value="Hydrochlorothiazide" score="0.49" ID="270905">hydrochlorothiazide</Semaphore>, unspecified medication and <Semaphore x="166901" class="Medicine" value="Aspirin" score="0.49" ID="212518">aspirin </Semaphore>for unspecified <Semaphore x="2010398" class="AnatomicStructure" value="Heart" score="1.00" ID="C12727">heart </Semaphore>condition and hydrocodone/paracetamol (<Semaphore x="1329258" class="Medicine" value="Vicodin" score="0.49" ID="216819">VICODIN</Semaphore>) and she was taking the concomitant medications during the events. On an unknown date while on <Semaphore x="1082033" class="Medicine" value="pregabalin" score="0.93" ID="239993">pregabalin </Semaphore><Semaphore x="4647171794141185" class="Medicine - pregabalin - Dose" value="200mg" score="0.49" ID="">200mg </Semaphore><Semaphore x="4647231923683329" class="Medicine - pregabalin - Frequency" value="three" score="0.49" ID="">three </Semaphore>times a day she experienced <Semaphore x="2915853" class="MedDRA LLT" value="Dry skin" score="1.00" ID="10013786"><Semaphore x="1864942" class="Disease or Finding" value="Dry Skin" score="1.00" ID="C74592">dry <Semaphore x="2418898" class="Disease or Finding" value="Pregnancy Related Skin Change" score="1.00" ID="C92856">skin</Semaphore></Semaphore>
     <Semaphore x="2418943" class="Disease or Finding" value="Pregnancy Stretch Mark" score="1.00" ID="C92857">
      <Semaphore x="2418920" class="Disease or Finding" value="Pregnancy Status" score="1.00" ID="C69218">
       </Semaphore></Semaphore></Semaphore>
    <Semaphore x="2418943" class="Disease or Finding" value="Pregnancy Stretch Mark" score="1.00" ID="C92857">
     <Semaphore x="2418920" class="Disease or Finding" value="Pregnancy Status" score="1.00" ID="C69218">
      <Semaphore x="2418898" class="Disease or Finding" value="Pregnancy Related Skin Change" score="1.00" ID="C92856">, <Semaphore x="2418898" class="Disease or Finding" value="Pregnancy Related Skin Change" score="1.00" ID="C92856">change </Semaphore>in skin </Semaphore></Semaphore></Semaphore>color and mentioned that <Semaphore x="1082033" class="Medicine" value="pregabalin" score="0.93" ID="239993">pregabalin </Semaphore>was not as effective as it was in the past". Relevant <Semaphore x="2091429" class="Disease or Finding" value="Laboratory Test Result" score="1.00" ID="C36292">lab </Semaphore>data was included unspecified <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore>work done in Nov2012 and the <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">result </Semaphore>of which were normal. She continued taking <Semaphore x="1082033" class="Medicine" value="pregabalin" score="0.93" ID="239993">pregabalin</Semaphore>. The clinical <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the above mentioned events was unknown.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>